CPX-351 Therapy for MDS After Hypomethylating Agent Failure
NCT03957876
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
4
Enrollment
OTHER
Sponsor class
Stopped
Slow Accrual
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
DRUG:
CPX-351
Sponsor
Case Comprehensive Cancer Center